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Abstract
A group of inherited blood defects is known as Thalassemia is among the world’s most prevalent hemoglobinopathies. 
Thalassemias are of two types such as Alpha and Beta Thalassemia. The cause of these defects is gene mutations 
leading to low levels and/or malfunctioning α and β globin proteins, respectively. In some cases, one of these 
proteins may be completely absent. α and β globin chains form a globin fold or pocket for heme (Fe++) attachment 
to carry oxygen. Genes for alpha and beta-globin proteins are present in the form of a cluster on chromosome 
16 and 11, respectively. Different globin genes are used at different stages in the life course. During embryonic 
and fetal developmental stages, γ globin proteins partner with α globin and are later replaced by β globin protein. 
Globin chain imbalances result in hemolysis and impede erythropoiesis. Individuals showing mild symptoms 
include carriers of alpha thalassemia or the people bearing alpha or beta-thalassemia trait. Alpha thalassemia 
causes conditions like hemolytic anemia or fatal hydrops fetalis depending upon the severity of the disease. Beta 
thalassemia major results in hemolytic anemia, growth retardation, and skeletal aberrations in early childhood. 
Children affected by this disorder need regular blood transfusions throughout their lives. Patients that depend on 
blood transfusion usually develop iron overload that causes other complications in the body systems like renal or 
hepatic impairment therefore, thalassemias are now categorized as a syndrome. The only cure for Thalassemias 
would be a bone marrow transplant, or gene therapy with currently no significant success rate. A thorough 
understanding of the molecular basis of this syndrome may provide novel insights and ideas for its treatment, as 
scientists have still been unable to find a permanent cure for this deadly disease after more than 87 years since 
it is first described in 1925.
Keywords: thalassemias, beta globin genes, hemoglobinopathies.
Resumo
Um grupo de defeitos sanguíneos hereditários é conhecido como talassemia e está entre as hemoglobinopatias mais 
prevalentes do mundo. As talassemias são de dois tipos, como talassemia alfa e beta. As causas desses defeitos são as 
mutações genéticas que levam a níveis baixos e/ou proteínas de globina com mau funcionamento, respectivamente. 
Em alguns casos, uma dessas proteínas pode estar completamente ausente. As cadeias de globina α e β formam 
uma dobra ou bolsa de globina para a fixação de heme (Fe ++) para transportar oxigênio. Os genes das proteínas 
alfa e beta globina estão presentes na forma de um cluster nos cromossomos 16 e 11, respectivamente. Diferentes 
genes de globina são usados  em diferentes estágios do curso de vida. Durante os estágios de desenvolvimento 
embrionário e fetal, as proteínas γ globina se associam à α globina e, posteriormente, são substituídas pela proteína 
β globina. Os desequilíbrios da cadeia de globina resultam em hemólise e impedem a eritropoiese. Indivíduos que 
apresentam sintomas leves incluem portadores de talassemia alfa ou as pessoas com traços de talassemia alfa ou 
beta. A talassemia alfa causa condições como anemia hemolítica ou hidropsia fetal fatal, dependendo da gravidade da 
doença. A beta talassemia principal resulta em anemia hemolítica, retardo de crescimento e aberrações esqueléticas 
na primeira infância. As crianças afetadas por esse distúrbio precisam de transfusões de sangue regulares ao longo 
da vida. Os pacientes que dependem de transfusão de sangue geralmente desenvolvem sobrecarga de ferro que 
causa outras complicações nos sistemas do corpo, como insuficiência renal ou hepática, portanto as talassemias 
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Hemoglobin is not only confined to the red blood 
cells (RBCs) but it can also be found in progenitor cells of 
RBCs, dopaminergic neurons of group A9 present in the 
ventrolateral midbrain of some rodents and primates, 
macrophages, cells of alveoli, and mesangial cells 
supporting the glomerular tuft inside the kidney are the 
other cells which contain hemoglobin. In these tissues, 
hemoglobin functions as an antioxidant and metabolic 
regulator to some extent rather than an oxygen supplier 
(Hughes and Pride, 2012).
The functional, practical exercises performed by 
hemoglobin other than gas transport include fertilization, 
signaling, adjustment of inflammatory reactions to defend 
and protect the cell. These exercises are proficiently 
executed while Hb is sequestered securely inside the 
boundaries of the RBCs. Outside the RBC limits, Hb 
disaggregates and jeopardizes the cell life as in severe 
cases, antioxidants become overwhelmed to clear free 
radicals that are produced during Hb oxidation (Mairbäurl 
and Weber, 2012).
Hemoglobin is a protein with four polypeptide subunits 
with 64,500 Da molecular weight. It consists of two α- and 
two β-chains of 141 and 146 amino acids each, respectively 
(Figure 1). In adults, the hemoglobin’s secondary structure 
of all polypeptide chains is mainly α-helical. HbA does not 
contain any β-strands or disulfide bonds. Unusually, it also 
lacks isoleucine. The β-chain of HbA comprises eight helical 
fragments, designated by letters A-H. The α-chain is quite 
similar but lacks helix D. Each polypeptide chain of HbA 
maintains a three-dimensional conformation, known as 
globin fold, just like a closely related monomeric protein, 
myoglobin (Mb). The globin fold is, in fact, an arrangement 
of helices due to which a cavity is formed that holds and 
attaches to a heme (Fe++) prosthetic group. A covalent 
bond is present between the NƐ2 atom of the F8His residue 
and the heme iron inside each polypeptide of the globin 
subunits. This heme/iron atom that is in the ferrous state 
has the potential to reversibly bind with specific gas ligands 
A dentist named Cooley first reported a progression 
of iron deficiency in infants leading to splenomegaly 
and bone deformation soon after their birth in 1925 
(Cunningham, 2010).
In 1932, Whipple and Bradford explained the pathology 
of the disease for the first time, and as most of the patients 
were found to be native to the Mediterranean range, they 
termed the condition as “thalassemia” (Rachmilewitz and 
Giardina, 2011).
Blood disorder types characterized by low levels or 
missing normal globin chains in the normal red blood cell 
protein hemoglobin are now characterized as thalassemia. 
There are four types of globin chains present named alpha 
(α) beta (β) gamma (γ) and delta (δ). Depending on which 
chain production is disturbed, the thalassaemias are termed 
as α-, β-, γ-, δ -, δβ-, or εγδβ-thalassaemias. Mostly inherited 
as a recessive trait, the most common types are α- and 
β-thalassaemias, that result from the deficiency of α- or 
β-globin proteins that are necessary for the production 
of normal hemoglobin molecule (HbA, α2β2) in an adult 
human (Taher and Cappellini, 2014).
As defined, thalassemia is a complex of various 
hereditary disorders of hemoglobin combination featuring 
insufficient production of at least one of the globin chains 
driving imbalanced globin-chain production, damaged 
hemoglobin eventually causes anemia (Cappellini et al., 
2014). Hemoglobin is a metalloprotein (Hb or Hgb) found 
inside the red blood cells (RBCs) of all the vertebrates 
(except a fish family Channichthyidae) and some 
invertebrates, functions as an oxygen-transporting vehicle 
(Burmester and Hankeln, 2014).
Inside the blood, hemoglobin acts as a carrier that 
conveys oxygen from lungs or gills to entire body tissues 
and upon reaching there, it unloads the oxygen that in turn 
is used in aerobic respiration to produce ATPs to run the 
metabolic processes of an organism (Zhao et al., 2019).
A hemoglobin molecule inside the mammalian RBCs 
could bind up to four oxygen molecules at a time, which 
in turn increases the blood oxygen binding capacity (OBC) 
seventy times, as the OBC (C
Hb
) of hemoglobin alone is 1.34 
O
2
 mL/gm Hb (Ali, 2018). Some amount of oxygen may 
also dissolve directly into the blood during respiration 
but that is only 1.5% of total oxygen carried through the 
blood (Molnar and Gair, 2013).
Hemoglobin is involved in transporting other gases 
too, it binds a portion of carbon dioxide (CO
2
) gas which 
is produced as a result of metabolic activities, in the form 
of carbaminohemoglobin, i.e., hemoglobin loaded with 
CO
2
, and contributing a fraction of 20–25% of the total CO
2
 
exhaled (Hughes and Pride, 2012). Hemoglobin additionally 
carries nitric oxide (NO), which an essential regulatory 
molecule, NO is bound to a thiol group of globin protein, 
discharging along with oxygen (Biagioli et al., 2009).
agora são classificadas como uma síndrome. A única cura para as talassemias seria um transplante de medula 
óssea ou terapia genética sem atualmente uma taxa de sucesso significativa. Uma compreensão completa da base 
molecular dessa síndrome pode fornecer novos insights e ideias para seu tratamento, já que os cientistas ainda 
não conseguiram encontrar uma cura permanente para essa doença mortal depois de mais de 87 anos desde que 
foi descrita pela primeira vez em 1925.
Palavras-chave: thalassemias, genes da beta globina, hemoglobinopatias.
Figure 1. Ultrastructure of the hemoglobin molecule.
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like oxygen, carbon monoxide, and nitric oxide (Hassan 
and Alhajouj, 2011). As already mentioned, hemoglobin 
comprises two α and two β-chains. Therefore, it can be 
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 subunit interfaces are mirror 
images of each other (Hamamy and Al-Allawi, 2013).
The human embryo and fetus normally develop with 
different hemoglobin variants i.e., Hb Portland-1 (ζ2γ2), 
Hb Gower-1 (ζ2ɛ2), Hb Gower-2 (α2ɛ2) and fetal Hb or HbF 
(α2γ2) (Kohne, 2011). Stage-specific combinations of globin 
genes are transcribed within the fetus during gestation, 
which leads to producing various forms of hemoglobin 
molecules such as several embryonic hemoglobins, 
hemoglobin A (HbA) and, hemoglobin F (HbF) (Shown in 
Table 1). Immature erythrocytes produce the embryonic 
hemoglobins (Gower 1, Gower 2, and Portland) in the 
yolk sac. They persist up to the 12th week of pregnancy. 
In the fifth week, Hemoglobin F (Hb F) appears which 
predominates during fetal life. Hb F is synthesized initially 
in the liver of the fetus and remains there for several weeks 
after birth. HbA prevails after birth, which originates in 
the bone marrow. Most common among other variants is 
Hemoglobin A (α2β2) usually with an amount of around 95% 
(Kaufman et al., 2021). The normal range of hemoglobin 
A2 (α2δ2) is 1.5–3.5% of the total hemoglobin in an adult. 
Though Hb A2 has no physiological importance in an adult 
its level may rise in case of alpha or beta chain reduction 
(Figueiredo, 2015) the mutations in delta globin genes along 
with beta-globin gene variations may also interfere with 
the beta-thalassemia diagnosis especially in the cases of 
beta-thalassemia trait (Hariharan et al., 2016). The gamma 
chain is synthesized late in the last trimester and at this 
stage, the Hb F (α2γ2) is only restricted in a small number 
of RBCs known as ‘F-cells’. Interestingly, in individuals 
having sickle cell anemias and beta-thalassemia, the Hb 
F level is quite elevated (Kaufman et al., 2021).
All genetic hemoglobin disorders fall under the broad 
term “hemoglobinopathy”. These are split further into 
two main categories, which are:
• Thalassemia syndromes (resulting in severe anemia 
and other related complications);
• Structural variants of hemoglobin (malfunctioning 
hemoglobin proteins).
Both occur due to mutated and deleted segments 
of α- or β-globin genes. Thalassemia is caused due to 
defects in the globin genes, which results in Hb synthesis 
disorders i.e., under or overproduction of globin chains. 
The structure of Hemoglobin in such cases remains normal. 
Abnormal hemoglobin only occurs when there is a change 
in the structure of Hb. There are many combinations of 
both forms like β0/β+-thalassemias, Hb/Sickle disease, 
and HbE/α-thalassemias. The conventional capabilities 
of the pathophysiology and various ailment patterns are 
restrained, resulting in limited possibilities to summarize 
them (Giardine et al., 2014).
The pathogenic hemoglobin protein also indicates the 
cells and organ types before and after birth in which it 
is originated (Table 2) (Mehdi and Al Dahmash, 2011; De 
Sanctis et al., 2017). Based on the affected globin chain, the 
thalassemias are arranged into alpha (α) or beta (β) types. 
The β thalassemia is found throughout the world while α 
thalassemia is more prevalent in the Mediterranean region, 
(Lippi and Mattiuzzi, 2020, De Sanctis et al., 2017) and China 
(Qin and Wu, 2009; Muncie Junior and Campbell, 2009).
1. Alpha Thalassemia
There are 2 copies of the alpha-globin gene in the human 
genome both located on chromosome 16, therefore in a 
normal diploid cell, 4 copies of the gene are available, to 
produce the protein. Alpha-thalassemia is caused by an 
underproduction of α-globin proteins due to mutation 
or deletion of one of the four α globin genes (Leung and 
Lao, 2012).
There are two phenotypes of α thalassemia recorded 
so far. α thalassemia I or minor and α thalassemia II with 
no clinical symptoms of thalassemia. It is now known that 
α thalassemia I is associated with the complete absence 
of α globin proteins and the other is merely a reduction 
in α globin expression. These two α thalassemia variants 
are now designated as thalassemia α° and thalassemia α+, 
respectively as shown in Table 3 (Haley, 2017).
Alpha (0) thalassemia – there are more than 20 different 
mutations described, resulting in the deletion of all the 
sets of α-globin genes. People having this deficiency are 
unable to synthesize normal α-globin and therefore cannot 
make any normal functioning A, F, or A2 hemoglobin. This 
prompts the onset of hydrops fetalis or “hemoglobin Bart”; 
children born with this disorder do not survive outside 
the uterus.
Alpha (+) thalassemia –more or less fifteen genetic 
mutations are reported, which result in limited α-globin 
protein synthesis generally because of the functional 
deletion of at least one alpha-globin gene.
Alpha (+) thalassemia is further sub-classified into 
four categories:
Table 1. Various globin genes and their subunits.
Subunit Gene Chromosome Expression
ζ-Globin HBζ1 16 Embryonic
HBζ2
α-Globin HBα1 16 Fetal and 
adult
HBα2
ɛ-Globin HBɛ 11 Embryonic
ɣ-Globin HBG1 (Aɣ) 11 Fetal
HBG2 (Gɣ)
β-Globin HBB 11 Adult
δ-Globin HBD 11 Adult
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 A- Thalassemia (-α/αα) occurs when three out of four 
functional α-genes are inherited. The individuals are 
referred to as asymptomatic carriers for α-thalassemia. 
Various terms used for this disorder are “alpha 
thalassemia minima”, “alpha thalassemia-2 trait”, 
and “heterozygosity for alpha (+) thalassemia minor”. 
These carriers are clinically normal or may have mild 
anemia;
 B- Thalassemia (-α/-α) condition is known as a trans-
deletion because two healthy alpha genes are inherited, 
one from each of the two chromosomes (-α/-α) whereas 
homozygosity for alpha (+) thalassemia (αα/--) (two 
on the same chromosome) is known as a “cis deletion” 
resulting in “alpha thalassemia minor” or “alpha 
thalassemia-1 trait”. Parents who are carriers of the cis 
deletion can have one out of four (25%) babies affected 
with alpha thalassemia major in every pregnancy;
 C- Hemoglobin H: when only one healthy alpha gene 
(-α/--) is inherited, it results in the massive production 
of hemoglobin H (Hb H) comprising tetramers of surplus 
beta chains. The disorder is named “Hb H disease”;
 D- Hemoglobin Bart’s disease: When all four alpha 
genes are lost, a situation occurs, that is life-threatening. 
Four gamma-globin chains are formed during the life 
of the fetus inside the womb which unites to frame 
irregular hemoglobin known as ‘hemoglobin Bart’s’ 
(Camacho et al., 1999).
Alpha thalassemia is different from beta-thalassemia in 
its pathophysiology. The shortage of α chain results in excess 
production of gamma or beta chains, which form Hb Bart’s 
Table 2. Types of Combination Hemoglobinopathies.
No. Type of hemoglobinopathy No. of a and b chains present
1. Hemoglobin D-Punjab – (α2βD2): one alpha, two betas, and one delta globin polypeptide chains.
2. Hemoglobin H - (β4): four β chains, might also be present in various types of αlpha 
thalassemia
3. Hemoglobin Barts – (γ4) four γ chains, may also present in α thalassemia variants.
4. Hemoglobin S – ( α2βS2) observed in individuals having sickle cell anaemia. A point mutation in 
the β-chain gene modifies the characteristics of haemoglobin,
5. Hemoglobin C (α2βC2) causes due to a change in the β-chain gene sequence results in a mild 
chronic hemolytic anaemia.
6. Hemoglobin E (α2βE2) A haemoglobin variant with the mutant β-chain gene causes anemia due 
to a slight chronic red cell hemolysis.
7. Hemoglobin |(AS) characterized by sickle cell trait and occurs due to the hybrid gene 
comprises of an adult and a sickle cell disease allele.
8. Hemoglobin SC disease A complex heterozygous hemoglobin having a gene causes sickle red 
cells, and the other encodes for Hemoglobin C [17].
Table 3. Thalassemia Syndromes and Genotypes.
Alpha Thalassemia α genes Globin Chains Hemoglobin Anemia
Normal αα/αα α2β2 A None
Silent Carrier αα/α- α2β2 A None
Trait α-/α- OR --/αα α2β2 A Mild
Hb H disease --/-α α2β2.β4 A, H Intermediate
Hydrops fetalis --/-- γ4, Barts Lethal
ζ2γ2, Portland
Beta Thalassemia β genes Globin Chains Hemoglobin Anemia
Normal β/β α2β2 A None
Thalassemia minor β+/β OR β0/β α2β2, α2δ2, α2γ2 A None
Thalassemia major β+/β+ OR α2β2, α2δ2, α2γ2 A, A2, F Severe
β0/β0 α2δ2, α2γ2 Severe
*HPFH γ/γ F Mild
*Hereditary Persistence of Fetal Hemoglobin.
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and Hb H, respectively. These dissolvable tetramers do not 
accumulate in the bone marrow, and thus erythropoiesis is 
more viable as compared with β-thalassemia. In any case, 
Hb H is not only unstable but also accumulate in red cells 
with time. Inclusion bodies created in this way are caught 
in the spleen and different parts of the microcirculation 
prompt to reduce red cell survival. Furthermore, both Hb 
Barts and Hb H have a very high oxygen affinity; because 
they have no α chains, there is no heme-heme interaction 
and their oxygen dissociation curves resemble myoglobin 
(Taher et al., 2018). In conclusion, there are Four subtypes 
of alpha thalassemia are there ranging from moderate to 
severe in their effects on the patient’s body (Lee et al., 2010).
1.1. Alpha thalassemia minor
It is an asymptomatic carrier condition that occurs due 
to the deletion of the one α- globin gene. This condition 
usually causes no symptoms or signs of anemia and does not 
need treatment due to negligible alpha protein deficiency; 
therefore, the hemoglobin appears to be normal (Leung 
and Lao, 2012). The term “silent carrier” is usually used to 
describe this condition because it is not easily diagnosed 
through standard hematological investigations. Only DNA 
analysis could detect this condition (Camacho et al., 1999).
1.2. Alpha thalassemia trait
The trait is also known as mild alpha-thalassemia. 
The patients are deficient in two alpha-globin genes. The 
affected individuals have RBCs smaller than usual and are 
mildly anemic but do not show any symptoms and may 
only be diagnosed by routine tests (Leung and Lao, 2012).
1.3. Alpha thalassemia intermedia
Also, it is known as hemoglobin H disease. Individuals 
lacking three alpha globin genes become severely anemic 
and mostly cannot survive without blood transfusion. 
Newborns who inherited alpha thalassemia intermedia 
seem healthy at birth but mainly develop anemia and 
splenomegaly as they approach the second year of his 
life. Hepatomegaly is not commonly reported, and there 
might be some relationship to the mental retardation in 
affected individuals. As hemolysis occurs in this type of 
anemia the tendency to develop respiratory infections, 
gallstones, and leg ulcers increases. Bone deformities are 
not usually found in hemoglobin H disease (Lee et al., 2010).
The imbalanced alpha and beta chain synthesis (that is 
usual) induces aggregation of beta chains inside the RBCs. 
Usually, beta chains are coupled with alpha chains only. 
Alpha thalassemia with three-gene deletions causes the 
beta chains to accumulate in gatherings of four, creating 
unusual hemoglobin, called “hemoglobin H”. This condition 
leads to “hemoglobin H disease”. This hemoglobin variant 
has two issues. First, it does not convey oxygen efficiently, 
making it practically useless to the cell. Secondly, 
hemoglobin H protein harms the cell membranes of RBCs, 
accelerating cell death. A combination of reduced alpha 
chain synthesis and red cell lysis in hemoglobin H disease 
creates severe and fatal anemia. Without treatment, most 
individuals do not survive and expire in their early teens 
or before (Camacho et al., 1999).
1.4. Alpha thalassemia major
“Hydrops fetalis” or alpha thalassemia major is a 
condition in which no alpha genes are found in the patients’ 
genome, resulting in four gamma-globin chains production 
by the fetus that produces malfunctioning hemoglobin 
known as hemoglobin Bart’s. Most affected individuals 
having Hemoglobin Bart’s cannot survive or otherwise die 
in just a few hours after birth (Lee et al., 2010).
Alpha thalassemia with four deletions in the gene has 
rarely been diagnosed in the uterus, especially in a family 
with a history of the disorder occurring in early childhood. 
Reportedly, some of these children have been saved through 
blood transfusions during pregnancy (Camacho et al., 1999).
2. Beta Thalassemia
Around 200 mutations of the beta-globin gene have been 
identified worldwide which produce beta-thalassemia. 
Unlike alpha thalassemia syndromes where deletion 
is usually the root cause, beta-thalassemia occurs due 
to mutations that influence all stages of beta-globin 
protein synthesis including transcription, translation, 
and beta-globin production durability. Two types of 
β-thalassemia, ß+, and ß° thalassemia are identified so 
far that lack beta chain production altogether (Table 1). 
Beta thalassemia major usually results when ß+ or ß° 
thalassemia occurs in homozygous condition. Occasionally, 
however, the compound heterozygous state for both ß+ 
and ß° thalassemia results in beta-thalassemia. In the 
case of homozygous ß° thalassemia, there is no Hb A, 
an abundance of HbF, and variable amounts of Hb A2. In 
individuals with homozygous ß+ thalassemia, the amount 
of Hb A is variable, Hb F is increased and distributed 
heterogeneously among RBCs whereas Hb A2 is normal, 
decreased, or elevated (Taylor et al., 2012).
The molecular variations in β thalassemia result in 
missing or diminished β chain generation. Alpha chain 
Synthesis remains unaffected, and therefore there is an 
unequal amount of globin chain generation that prompts an 
abundance of α chains. They are not stable in the absence of 
their normal partners and precipitate in the RBC precursors, 
which interferes with RBC processing. As a result, there 
is a variable level of intramedullary destruction of RBCs 
precursors (i.e. ineffective erythropoiesis). The RBCs having 
α chain incorporated when enter the bloodstream interfere 
with their segment via microcirculation, exclusively in 
the spleen. Such cells demonstrate a high variability in 
the structure of membrane and penetrability and are 
short-lived. Hence, anemia occurs due to both abnormal 
erythropoiesis and shortened cell survival. The anemia 
stimulates erythropoietin production resulting in bone 
marrow expansion, which consequently causes deformed 
skull and large bones ref needed. Since the spleen is 
overburdened and required to remove a continuous stream 
of abnormal red cells, enlarges before it exhausts ultimately 
(Borgna-Pignatti and Gamberini, 2011).
Generally, three categories of beta-thalassemia have 
been recognized, ranging from mild to severe by affecting 
the patient’s body.
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2.1. Beta thalassemia minor
Also known as thalassemia trait due to one of 
malfunctioning beta-globin genes, but this generally 
causes no significant problem in the proper functioning 
of hemoglobin protein (Hay and Weatherall, 2017). When 
there is an excess of alpha chains, the mechanism that 
switches off gamma chain expression does not work 
effectively, thus the levels of Hb F remain somewhat 
elevated in these patients. The alpha chains consolidate 
with the accessible beta chains bringing about diminished 
levels of hemoglobin rest of the surplus alpha chains 
empower the over-production of delta chains (Jha and Jha, 
2014) Affected individuals have a 1:1 chance to pass the 
thalassemia minor trait to their child (Memon, et al., 2017).
2.2. Beta thalassemia intermedia
A condition where the absence of beta polypeptide 
in the hemoglobin is sufficient to bring about more 
extreme anemia and serious medical issues, including 
shortness of breath, bone disfigurements, mild jaundice, 
and an enlarged spleen. The condition is characterized 
by having two abnormal genes in affected individuals 
while still producing some beta-globin. Depending on 
the level and functional competence of beta-Globin is a 
broad range in the clinical severity of this disease (Hay 
and Weatherall, 2017).
2.3. Beta thalassemia major
It is also known as “Cooley’s anemia” and is the most 
severe form of beta-thalassemia with absent beta-globin 
synthesis thus preventing the production of significant 
amounts of Hb A. The severe irregularity of globin chain 
synthesis (alpha >> beta) brings about extreme microcytic 
hypochromic anemia. Within the RBCs surplus unpaired 
alpha-globin chains precipitate, this harms the plasma 
membranes of RBCs and brings about intravascular 
hemolysis. Besides, premature death/apoptosis/lysis/
necrosis of erythroid precursors reduces the number of 
RBCs even further. The severe anemia results in hypoxia 
and the resulting EPO causes hyperplasia in the bone 
marrow and will lead to extramedullary hematopoiesis 
(Cunningham, 2010).
During childbirth, the infant with thalassemia 
major appears to be healthy. This is because there is a 
predominance of fetal hemoglobin (Hb F) during gestation. 
which lacks any beta chains. Anemia starts to appear a 
few months after birth, as the infant switches over from 
gamma to beta globulin. The infant’s growth retards and 
often has issues (due to poor oxygen absorbance in the 
body with significant anemia), episodes of fever to which 
the severe sickliness inclines the small stature, slow bowel 
movement, and other intestinal issues. If untreated, it will 
cause the enlargement of organs like the spleen, liver, 
and heart, and bones to become weak and brittle. The 
condition results in death before age twenty (Hay and 
Weatherall, 2017).
Regular blood transfusions and extensive continuous 
therapeutic care are required throughout life in this type 
of anemia. After some time, these successive transfusions 
prompt iron overload in the body. Without treatment, this 
overabundant iron will be stored in the liver, heart, spleen, 
and other organs and could prompt a sudden death due 
to major systemic failure (Cunningham, 2010).
Silent carriers of Alpha thalassemia lack signs or side 
effects of the disorder. Individuals affected by alpha 
or beta thalassemia disorders might have a slight iron 
deficiency. It might be an indication. Side effects might 
be more adverse in the expecting women, or the people 
with anxiety, or malnourished. Evidence may include 
fatigue. This might be the main side effect that a person 
with beta-thalassemia minor shows. Exhaustion is created 
by the diminished oxygen-conveying limit of the RBCs, 
bringing about reduced oxygenation for cells and tissues 
and causing pale skin tone due to insufficient oxygen in 
the blood (Bhatia et al., 2014).
Over the past three decades, regular blood transfusions 
have dramatically eliminated the complicity of thalassemia 
and bone marrow transplantation, enhanced the quality 
of life-permitting normal development throughout 
childhood and extended life span. But, transfusion results 
in a complication due to iron overload (Haidar et al., 2011).
Regular blood transfusion leads to iron overload-related 
complications including hormonal complications such as 
growth retardation, sexual immaturity, diabetes mellitus, 
and insufficiency of the parathyroid, thyroid, pituitary, 
adrenal glands, dilated myocardiopathy, liver fibrosis, 
and cirrhosis (Behera et al., 2014; Mokhtar et al., 2013; 
Goulas et al., 2012; Borgna-Pignatti and Gamberini, 2011).
In non-transfused thalassemic patients, the spleen, liver, 
heart, and bone marrow become significantly enlarged was 
stated before. Expansion of marrow cavities and thinning 
of cortices produce a variety of bone abnormalities in 
patients who are not optimally transfused (Bhatia et al., 
2014). The result of bone biopsies from non-transfused 
thalassemic patients shows osteoporosis with increased 
bone resorption, decreased mineralization, and fewer 
bone-forming sites (Behera et al., 2014).
Over the past few decades, there has been a 
tremendous advancement in the field of clinical and 
genetics research. Many countries have nearly wiped out 
the disease by making better decisions like mass testing 
for hemoglobinopathies before marriage or childbirth. 
Thalassemia is now being considered to be treated beyond 
bone marrow transplantation which has always been 
the last hope to survive for a thalassemia patient. Today, 
allogeneic hematopoietic stem cell transplant (HSCT) from 
human leukocyte antigen (HLA)‐matched sibling or other 
donors is the only treatment for thalassemia patients with 
> 90% transfusion independent survival rate in the patients 
transplanted with sibling matched donors. However, the 
treatment is possible in the individuals at a very young 
age. The disease-free survival rate depends upon the 
factors like HLA- matching, age and iron overloading 
etc. (Soni, 2020). Scientists have developed better tools 
to treat genetic disorders like stem cell technology and 
gene therapy to avoid tissue rejection in recipients. The 
therapy adds a corrective gene whose product combines 
with α-globin to produce functional hemoglobin, thereby 
reversing the ineffective red blood cell production seen 
in β-thalassemia. However, the technique is much costly 
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(~ $1.6 billion) which could not be easy to afford by the 
patient’s family or the healthcare providers (Harrison, 2019).
A novel CRISPR technology to edit faulty genes is a new 
game changer that showed promising results in disease 
models that made it a new hope to the diseased. The 
CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats) along with the CRISPR- associated system, Cas 
(known as Crispr-Cas) is a powerful gene editing tool which 
has revolutionized the field of molecular biology in terms 
of gene therapies to treat hereditary genetic disorders 
(Lino et al., 2018). CRISPR Cas system enables programmable 
targeting of single base insertion or deletion (Indels) 
at a particular site of the genomic DNA. Frangoul et al. 
(2021) has successfully used the Crispr tool to edit the 
hematopoietic stem cells in order to downregulate the B 
globin gene to reduce the faulty beta globin chains and 
enhance the reactivation of fetal hemoglobin (G globin 
protein) to overcome the anemia eventually reducing 
the blood dependency in the thalassemia patients. The 
patients under trial were transplanted with these edited 
stem cells. The trial had shown promising results and no 
discrepancy has been reported so far.
Acknowledgements
We thank all our colleagues at the University of 
Sheffield, United Kingdom, King Abdulaziz University 
Jeddah Saudi Arabia, Women University of Azad Kashmir, 
Bagh Pakistan and University of Azad Jammu and Kashmir 
Muzaffarabad, Pakistan.
References
ALI, A.H.A.E., 2018. Normal reference values of some hematological 
parameters among adult sudanese people in elmatama locality. 
Republic of Sudan: Shendi University. Doctoral Dissertation 
in Haematology.
BEHERA, S., DIXIT, S., BULLIYYA, G. and KAR, S.K., 2014. Fat-soluble 
antioxidant vitamins, iron overload and chronic malnutrition 
in β-thalassemia major. Indian Journal of Pediatrics, vol. 81, no. 
3, pp. 270-274. http://dx.doi.org/10.1007/s12098-013-1162-0. 
PMid:24062266.
BHATIA, M., JIN, Z., BAKER, C., GEYER, M.B., RADHAKRISHNAN, 
K., MORRIS, E., SATWANI, P., GEORGE, D., GARVIN, J., DEL 
TORO, G., ZUCKERMAN, W., LEE, M.T., LICURSI, M., HAWKS, 
R., SMILOW, E., BAXTER-LOWE, L.A., SCHWARTZ, J. and CAIRO, 
M.S., 2014. Reduced toxicity, myeloablative conditioning with 
BU, fludarabine, alemtuzumab and SCT from sibling donors in 
children with sickle cell disease. Bone Marrow Transplantation, 
vol. 49, no. 7, pp. 913-920. http://dx.doi.org/10.1038/bmt.2014.84. 
PMid:24797180.
BIAGIOLI, M., PINTO, M., CESSELLI, D., ZANINELLO, M., LAZAREVIC, 
D., RONCAGLIA, P., SIMONE, R., VLACHOULI, C., PLESSY, C., 
BERTIN, N., BELTRAMI, A., KOBAYASHI, K., GALLO, V., SANTORO, 
C., FERRER, I., RIVELLA, S., BELTRAMI, C.A., CARNINCI, P., RAVIOLA, 
E. and GUSTINCICH, S., 2009. Unexpected expression of α-and 
β-globin in mesencephalic dopaminergic neurons and glial 
cells. Proceedings of the National Academy of Sciences of the 
United States of America, vol. 106, no. 36, pp. 15454-15459. 
http://dx.doi.org/10.1073/pnas.0813216106. PMid:19717439.
BORGNA-PIGNATTI, C. and GAMBERINI, M.R., 2011. Complications 
of thalassemia major and their treatment. Expert Review of 
Hematology, vol. 4, no. 3, pp. 353-366. http://dx.doi.org/10.1586/
ehm.11.29. PMid:21668399.
BURMESTER, T. and HANKELN, T., 2014. Function and evolution 
of vertebrate globins. Acta Physiologica (Oxford, England), vol. 
211, no. 3, pp. 501-514. http://dx.doi.org/10.1111/apha.12312. 
PMid:24811692.
CAMACHO, L.H., WILAIRATANA, P., WEISS, G., MERCADER, M.A., 
BRITTENHAM, G.M., LOOAREESUWAN, S. and GORDEUK, V.R., 
1999. The eosinophilic response and haematological recovery 
after treatment for Plasmodium falciparum malaria. Tropical 
Medicine & International Health, vol. 4, no. 7, pp. 471-475. http://
dx.doi.org/10.1046/j.1365-3156.1999.00426.x. PMid:10470337.
CAPPELLINI, M.D., COHEN, A., PORTER, J., TAHER, A. and VIPRAKASIT, 
V., 2014. Guidelines for the management of transfusion dependent 
thalassaemia (TDT). Nicosia, Cyprus: Thalassaemia International 
Federation, pp. 148-149.
CUNNINGHAM, M.J., 2010. Update on thalassemia: clinical care 
and complications. Hematology/Oncology Clinics of North 
America, vol. 24, no. 1, pp. 215-227. http://dx.doi.org/10.1016/j.
hoc.2009.11.006. PMid:20113904.
DE SANCTIS, V., KATTAMIS, C., CANATAN, D., SOLIMAN, A.T., 
ELSEDFY, H., KARIMI, M., DAAR, S., WALI, Y., YASSIN, M., 
SOLIMAN, N., SOBTI, P., AL JAOUNI, S., EL KHOLY, M., FISCINA, 
B. and ANGASTINIOTIS, M., 2017. β-thalassemia distribution 
in the old world: an ancient disease seen from a historical 
standpoint. Mediterranean Journal of Hematology and Infectious 
Diseases, vol. 9, no. 1, pp. e2017018. http://dx.doi.org/10.4084/
mjhid.2017.018. PMid:28293406.
FIGUEIREDO, M.S., 2015. The importance of hemoglobin A2 
determination. Revista Brasileira de Hematologia e Hemoterapia, 
vol. 37, no. 5, pp. 287-289. http://dx.doi.org/10.1016/j.
bjhh.2015.06.002. PMid:26408359.
FRANGOUL, H., ALTSHULER, D., CAPPELLINI, M.D., CHEN, Y.S., 
DOMM, J., EUSTACE, B.K., FOELL, J., DE LA FUENTE, J., GRUPP, 
S., HANDGRETINGER, R., HO, T.W., KATTAMIS, A., KERNYTSKY, 
A., LEKSTROM-HIMES, J., LI, A.M., LOCATELLI, F., MAPARA, M.Y., 
DE MONTALEMBERT, M., RONDELLI, D., SHARMA, A., SHETH, S., 
SONI, S., STEINBERG, M.H., WALL, D., YEN, A. and CORBACIOGLU, 
S., 2021. CRISPR-Cas9 gene editing for sickle cell disease and 
β-thalassemia. The New England Journal of Medicine, vol. 384, 
no. 3, pp. 252-260. http://dx.doi.org/10.1056/NEJMoa2031054. 
PMid:33283989.
GIARDINE, B., BORG, J., VIENNAS, E., PAVLIDIS, C., MORADKHANI, 
K., JOLY, P., BARTSAKOULIA, M., RIEMER, C., MILLER, W., TZIMAS, 
G., WAJCMAN, H., HARDISON, R.C. and PATRINOS, G.P., 2014. 
Updates of the HbVar database of human hemoglobin variants 
and thalassemia mutations. Nucleic Acids Research, vol. 42, no. 
Database issue, pp. D1063-D1069. http://dx.doi.org/10.1093/
nar/gkt911. PMid:24137000.
GOULAS, V., KOURAKLI-SYMEONIDIS, A. and CAMOUTSIS, C., 
2012. Comparative effects of three iron chelation therapies 
on the quality of life of greek patients with homozygous 
transfusion-dependent Beta-thalassemia. International 
Scholarly Research Notices, vol. 2012, pp. 139862. http://dx.doi.
org/10.5402/2012/139862. PMid:23316378.
HAIDAR, R., MUSALLAM, K.M. and TAHER, A.T., 2011. Bone disease 
and skeletal complications in patients with β thalassemia major. 
Bone, vol. 48, no. 3, pp. 425-432. http://dx.doi.org/10.1016/j.
bone.2010.10.173. PMid:21035575.
HALEY, K., 2017. Congenital hemolytic anemia. Medicina Clínica, 
vol. 101, no. 2, pp. 361-374. http://dx.doi.org/10.1016/j.
mcna.2016.09.008. PMid:28189176.
Brazilian Journal of Biology, 2023, vol. 83, e2460628/8
Shafique, F. et al.
MAIRBÄURL, H. and WEBER, R.E., 2012. Oxygen transport by 
hemoglobin. Comprehensive Physiology, vol. 2, no. 2, pp. 1463-
1489. http://dx.doi.org/10.1002/cphy.c080113. PMid:23798307.
MEHDI, S.R. and AL DAHMASH, B.A., 2011. A comparative study of 
hematological parameters of α and β thalassemias in a high 
prevalence zone: saudi Arabia. Indian Journal of Human Genetics, 
vol. 17, no. 3, pp. 207-211. http://dx.doi.org/10.4103/0971-
6866.92106. PMid:22345994.
MEMON, A.S., MEMON, R., MUHAMMAD, A.T., ALI, S.A. and 
SIDDIQUI, A.J., 2017. Splenectomy: does it help in patients with 
thalassemia major. Journal of Liaquat University of Medical and 
Health Sciences, vol. 16, pp. 1-12. http://dx.doi.org/10.22442/
jlumhs.171610500.
MOKHTAR, G.M., GADALLAH, M., EL SHERIF, N.H. and ALI, H.T., 
2013. Morbidities and mortality in transfusion-dependent 
beta-thalassemia patients (single-center experience). Pediatric 
Hematology and Oncology, vol. 30, no. 2, pp. 93-103. http://
dx.doi.org/10.3109/08880018.2012.752054. PMid:23301991.
MOLNAR, C. and GAIR, J., 2013. Transport of gases in human bodily 
fluids. In: C. MOLNAR and J. GAIR, eds. Concepts of Biology: 
1st Canadian edition. Victoria:  OpenStax College, chap. 20.4.
MUNCIE JUNIOR, H.L. and CAMPBELL, J.S., 2009. Alpha and beta 
thalassemia. American Family Physician, vol. 80, no. 4, pp. 339-
344. PMid:19678601.
QIN, X. and WU, J., 2009. Study on α-thalassemia and hematological 
parameter in Li Nationality pregnant women in Hainan province. 
Zhongguo Fuyou Baojian, vol. 24, no. 32, pp. 4590-4592.
RACHMILEWITZ, E.A. and GIARDINA, P.J., 2011. How I treat 
thalassemia. Blood, vol. 118, no. 13, pp. 3479-3488. http://
dx.doi.org/10.1182/blood-2010-08-300335. PMid:21813448.
SONI, S., 2020. Gene therapies for transfusion dependent β‐
thalassemia: current status and critical criteria for success. 
American Journal of Hematology, vol. 95, no. 9, pp. 1099-1112. 
http://dx.doi.org/10.1002/ajh.25909. PMid:32562290.
TAHER, A.T. and CAPPELLINI, M.D., 2014. Management of non-
transfusion-dependent thalassemia: a practical guide. Drugs, 
vol. 74, no. 15, pp. 1719-1729. http://dx.doi.org/10.1007/s40265-
014-0299-0. PMid:25255924.
TAHER, A.T., WEATHERALL, D.J. and CAPPELLINI, M.D., 2018. 
Thalassaemia. Lancet, vol. 391, no. 10116, pp. 155-167. http://
dx.doi.org/10.1016/S0140-6736(17)31822-6. PMid:28774421.
TAYLOR, S.M., PAROBEK, C.M. and FAIRHURST, R.M., 2012. 
Haemoglobinopathies and the clinical epidemiology of malaria: 
a systematic review and meta-analysis. The Lancet. Infectious 
Diseases, vol. 12, no. 6, pp. 457-468. http://dx.doi.org/10.1016/
S1473-3099(12)70055-5. PMid:22445352.
ZHAO, Y., LI, Y., CHEN, P., LI, S., LUO, J. and XIA, H., 2019. Performance 
comparison of blood collection tubes as liquid biopsy storage 
system for minimizing cf DNA contamination from genomic 
DNA. Journal of Clinical Laboratory Analysis, vol. 33, no. 2, pp. 
e22670. http://dx.doi.org/10.1002/jcla.22670. PMid:30191594.
HAMAMY, H.A. and AL-ALLAWI, N.A., 2013. Epidemiological profile 
of common haemoglobinopathies in Arab countries. Journal 
of Community Genetics, vol. 4, no. 2, pp. 147-167. http://dx.doi.
org/10.1007/s12687-012-0127-8. PMid:23224852.
HARIHARAN, P., COLACO, S., COLAH, R., GHOSH, K. and NADKARNI, 
A., 2016. Delta globin gene variations leading to reduction in 
HbA2 levels. International Journal of Laboratory Hematology, 
vol. 38, no. 6, pp. 610-615. http://dx.doi.org/10.1111/ijlh.12548. 
PMid:27461962.
HARRISON, C., 2019. First gene therapy for β-thalassemia approved. 
Nature Biotechnology, vol. 37, no. 10, pp. 1102-1103. http://dx.doi.
org/10.1038/d41587-019-00026-3. PMid:31578501.
HASSAN, F.M. and ALHAJOUJ, Z.Y., 2011. Hemoglobin variant in 
Al-Madina Al-Mnora City, Saudi Arabia. Pakistan Journal of 
Medical Research, vol. 50, no. 4, pp. 145.
HAY, D. and WEATHERALL, D.J., 2017. Thalassaemias. eLS, 1-6. In 
press. https://doi.org/10.1002/9780470015902.a0002274.pub3.
HUGHES, J.M.B. and PRIDE, N.B., 2012. Examination of the carbon 
monoxide diffusing capacity (DLCO) in relation to its KCO and 
VA components. American Journal of Respiratory and Critical Care 
Medicine, vol. 186, no. 2, pp. 132-139. http://dx.doi.org/10.1164/
rccm.201112-2160CI.
JHA, R. and JHA, S., 2014. Beta thalassemia-a review. Journal of 
Pathology of Nepal, vol. 4, no. 8, pp. 663-671. http://dx.doi.
org/10.3126/jpn.v4i8.11609.
KAUFMAN, D.P., KHATTAR, J. and LAPPIN, S.L., 2021 [viewed 29 
November 2020]. Physiology, fetal hemoglobin [online]. Treasure 
Island (FL): StatPearls. Available from: https://www.ncbi.nlm.
nih.gov/books/NBK500011
KOHNE, E., 2011. Hemoglobinopathies: clinical manifestations, 
diagnosis, and treatment. Deutsches Ärzteblatt International, 
vol. 108, no. 31-32, pp. 532-540. http://dx.doi.org/10.3238/
arztebl.2011.0532. PMid:21886666.
LEE, S.T., YOO, E.H., KIM, J.Y., KIM, J.W. and KI, C.S., 2010. 
Multiplex ligation‐dependent probe amplification screening 
of isolated increased HbF levels revealed three cases of novel 
rearrangements/deletions in the β‐globin gene cluster. British 
Journal of Haematology, vol. 148, no. 1, pp. 154-160. http://
dx.doi.org/10.1111/j.1365-2141.2009.07927.x. PMid:19807730.
LEUNG, T.Y. and LAO, T.T., 2012. Thalassaemia in pregnancy. Best 
Practice & Research. Clinical Obstetrics & Gynaecology, vol. 26, no. 
1, pp. 37-51. http://dx.doi.org/10.1016/j.bpobgyn.2011.10.009. 
PMid:22079388.
LINO, C.A., HARPER, J.C., CARNEY, J.P. and TIMLIN, J.A., 2018. 
Delivering CRISPR: a review of the challenges and approaches. 
Drug Delivery, vol. 25, no. 1, pp. 1234-1257. http://dx.doi.org/1
0.1080/10717544.2018.1474964. PMid:29801422.
LIPPI, G. and MATTIUZZI, C., 2020. Updated worldwide epidemiology 
of inherited erythrocyte disorders. Acta Haematologica, vol. 
143, no. 3, pp. 196-203. http://dx.doi.org/10.1159/000502434. 
PMid:31550707.
